HRP20231060T1 - Pripravci peptida glp-1 i njihova priprava - Google Patents

Pripravci peptida glp-1 i njihova priprava Download PDF

Info

Publication number
HRP20231060T1
HRP20231060T1 HRP20231060TT HRP20231060T HRP20231060T1 HR P20231060 T1 HRP20231060 T1 HR P20231060T1 HR P20231060T T HRP20231060T T HR P20231060TT HR P20231060 T HRP20231060 T HR P20231060T HR P20231060 T1 HRP20231060 T1 HR P20231060T1
Authority
HR
Croatia
Prior art keywords
hydroxybenzoyl
amino
caprylic acid
lubricant
filler
Prior art date
Application number
HRP20231060TT
Other languages
English (en)
Croatian (hr)
Inventor
Tue Hansen
Thomas Vilhelmsen
Helle Eliasen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231060(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20231060T1 publication Critical patent/HRP20231060T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HRP20231060TT 2012-03-22 2013-03-15 Pripravci peptida glp-1 i njihova priprava HRP20231060T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12160743 2012-03-22
US201361748840P 2013-01-04 2013-01-04
EP13153459 2013-01-31
EP18188815.7A EP3488857B9 (en) 2012-03-22 2013-03-15 Compositions of glp-1 peptides and preparation thereof

Publications (1)

Publication Number Publication Date
HRP20231060T1 true HRP20231060T1 (hr) 2023-12-22

Family

ID=49221868

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20231060TT HRP20231060T1 (hr) 2012-03-22 2013-03-15 Pripravci peptida glp-1 i njihova priprava
HRP20181447TT HRP20181447T1 (hr) 2012-03-22 2013-03-15 Pripravci glp-1 peptida i njihova priprava

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181447TT HRP20181447T1 (hr) 2012-03-22 2013-03-15 Pripravci glp-1 peptida i njihova priprava

Country Status (22)

Country Link
US (6) US10933120B2 (enExample)
EP (3) EP2827885B1 (enExample)
JP (1) JP6001158B2 (enExample)
KR (1) KR102072202B1 (enExample)
CN (2) CN104203266B (enExample)
AU (2) AU2013234496B2 (enExample)
BR (1) BR112014023374B1 (enExample)
CA (1) CA2868188A1 (enExample)
DK (1) DK2827885T3 (enExample)
ES (2) ES2952874T3 (enExample)
HR (2) HRP20231060T1 (enExample)
HU (2) HUE039406T2 (enExample)
LT (1) LT2827885T (enExample)
MX (1) MX353067B (enExample)
MY (1) MY171146A (enExample)
PL (2) PL2827885T3 (enExample)
RS (2) RS64460B1 (enExample)
RU (1) RU2641198C3 (enExample)
SI (1) SI2827885T1 (enExample)
SM (1) SMT201800491T1 (enExample)
WO (1) WO2013139694A1 (enExample)
ZA (1) ZA201406250B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
KR102266299B1 (ko) * 2012-03-22 2021-06-18 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es) * 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2014261336B2 (en) * 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN108606957A (zh) * 2016-12-13 2018-10-02 南京星银药业集团有限公司 一种含索马鲁肽的口服缓释制剂及其制备方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
US11666637B2 (en) * 2018-03-09 2023-06-06 Northwestern University Insulin-loaded metal-organic frameworks
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP7422754B2 (ja) 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
CN111265654B (zh) * 2018-12-05 2023-05-16 江苏恒瑞医药股份有限公司 Glp-1类似物的药物组合物及其制备方法
WO2020127950A1 (en) * 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
MY210034A (en) * 2019-03-15 2025-08-22 Novo Nordisk As Process for spray drying a glp-1 peptide
EP4009958A1 (en) 2019-08-07 2022-06-15 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP4009957B1 (en) * 2019-08-07 2023-10-11 Novo Nordisk A/S Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP7767264B2 (ja) * 2019-09-02 2025-11-11 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
JP2023500031A (ja) 2019-11-07 2023-01-04 ノヴォ ノルディスク アー／エス Ｐｃｓｋ９阻害剤およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
JP7777085B2 (ja) * 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
JP2024518058A (ja) * 2021-05-07 2024-04-24 イーライ リリー アンド カンパニー 浸食性錠剤
US20230000764A1 (en) * 2021-06-11 2023-01-05 Boa Nutrition, Inc. Pressurized nutritional supplement delivery
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
MX2024000768A (es) * 2021-07-15 2024-02-12 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
US20240294466A1 (en) 2021-07-16 2024-09-05 Novo Nordisk A/S Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
JP2024543196A (ja) * 2021-12-01 2024-11-19 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｇｌｐ－１及びｇｉｐ受容体二重アゴニストの医薬組成物並びにその使用
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
CA3265745A1 (en) * 2022-08-25 2024-02-29 Univ British Columbia Mucoadhesive pharmaceutical form for the unidirectional release of therapeutic peptidic particles
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
CN116785412B (zh) * 2023-07-27 2025-02-28 重庆宸安生物制药有限公司 一种glp-1类似物口服递送组合物
WO2025037595A1 (ja) * 2023-08-14 2025-02-20 三生医薬株式会社 吸収促進造粒物およびその製造方法、医薬組成物、並びに組み合わせ剤
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025146144A1 (zh) * 2024-01-05 2025-07-10 成都国为生物医药有限公司 一种地非法林的口服药物组合物
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
CN118370728B (zh) * 2024-06-24 2024-11-08 山东则正医药技术有限公司 一种glp-1ra载药纳米颗粒和制剂及其制备方法

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219575A (en) 1986-03-12 1990-04-26 Glaxo Group Ltd Phosphate, substituted alkoxy, or amino-carbonyloxy derivatives of milbemycin, and pesticidal compositions
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
PL310897A1 (en) 1993-03-29 1996-01-08 Univ Cincinnati Analogues of yy peptide and their application
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0803255A4 (en) 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0941114B1 (en) 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides
CA2271788A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
CN1311773A (zh) 1998-06-08 2001-09-05 先灵公司 神经肽y5受体拮抗剂
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
JP2002523333A (ja) 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
SG125915A1 (en) 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
WO2000066629A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
RU2283092C2 (ru) 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
JP4417113B2 (ja) * 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP2277527A3 (en) 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
BRPI0412458A (pt) 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
GB2427550B (en) 2004-03-17 2007-05-30 7Tm Pharma As Y2/Y4 selective receptor agonists for therapeutic interventions
CN101361967A (zh) 2004-03-17 2009-02-11 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EA013518B1 (ru) 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
EP1750729A2 (en) 2004-05-06 2007-02-14 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
CA2565188C (en) 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
CA2573512C (en) 2004-07-12 2014-09-23 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
ES2540929T3 (es) 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
AU2006228525A1 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AR053495A1 (es) 2005-05-26 2007-05-09 Bristol Myers Squibb Co Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
CA2614619A1 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
WO2007009894A2 (en) 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
HRP20150186T1 (hr) 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US7851590B2 (en) 2005-09-21 2010-12-14 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
JP2009508885A (ja) 2005-09-21 2009-03-05 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
US20080255048A1 (en) 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
AU2006324076A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
EP1959987A2 (en) 2005-12-08 2008-08-27 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
CA2656019C (en) 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
KR101081149B1 (ko) 2006-09-07 2011-11-07 에미스페어 테크놀로지스, 인코포레이티드 Ｓｎａｃ(살카프로제이트 나트륨)의 제조 방법
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
PE20080845A1 (es) 2006-09-22 2008-08-13 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008070543A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
BRPI0808517A2 (pt) 2007-03-02 2014-08-19 Novartis Ag Administração oral de uma calcitonina
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2171080A4 (en) 2007-06-12 2010-10-27 Glaxosmithkline Llc PROCESS FOR DETECTING PROTEIN IN PLASMA
US8093689B2 (en) * 2007-07-02 2012-01-10 Infineon Technologies Ag Attachment member for semiconductor sensor device
US20100279930A1 (en) 2007-07-09 2010-11-04 Stephen Robert Bloom Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
WO2009032749A2 (en) 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
ES2550363T3 (es) 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009040019A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
MX2010011845A (es) 2008-05-16 2010-11-22 Novo Nordisk As Agonistas del receptor y2 y/o y4 de larga accion.
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
ES2375832T3 (es) 2008-10-15 2012-03-06 Bayer Cropscience Ag Uso de ditiin-tetracarboximidas para combatir hongos titopatógenos.
CA2741921A1 (en) 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
JP2013505221A (ja) 2009-09-18 2013-02-14 ノヴォ ノルディスク アー／エス 長時間作用性ｙ２受容体アゴニスト
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
AU2011245980A1 (en) 2010-04-30 2012-11-08 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
RU2600440C3 (ru) * 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
PL2866825T3 (pl) 2012-07-01 2021-02-22 Novo Nordisk A/S <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CA2909045C (en) 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante

Also Published As

Publication number Publication date
CN104203266B (zh) 2017-12-26
US11759502B2 (en) 2023-09-19
US20150072926A1 (en) 2015-03-12
LT2827885T (lt) 2018-10-10
AU2013234496B2 (en) 2017-07-27
AU2013234496A1 (en) 2014-09-11
EP4324475A1 (en) 2024-02-21
BR112014023374A2 (pt) 2017-07-11
RS57727B1 (sr) 2018-12-31
BR112014023374B1 (pt) 2021-09-21
RU2641198C3 (ru) 2021-12-10
US20210162012A1 (en) 2021-06-03
AU2017251814B2 (en) 2019-06-13
AU2017251814A1 (en) 2017-11-16
CA2868188A1 (en) 2013-09-26
MX2014010685A (es) 2014-10-13
JP6001158B2 (ja) 2016-10-05
EP3488857A1 (en) 2019-05-29
CN107812181A (zh) 2018-03-20
US11759503B2 (en) 2023-09-19
SI2827885T1 (sl) 2018-10-30
ZA201406250B (en) 2022-05-25
HRP20181447T1 (hr) 2018-11-02
EP2827885A1 (en) 2015-01-28
US10933120B2 (en) 2021-03-02
WO2013139694A1 (en) 2013-09-26
US20250195618A1 (en) 2025-06-19
EP3488857B1 (en) 2023-06-07
ES2952874T3 (es) 2023-11-06
BR112014023374A8 (pt) 2018-01-16
KR20140138873A (ko) 2014-12-04
CN107812181B (zh) 2022-06-17
RU2641198C2 (ru) 2018-01-16
HUE039406T2 (hu) 2018-12-28
EP3488857B9 (en) 2023-10-04
DK2827885T3 (en) 2018-10-08
MX353067B (es) 2017-12-19
US11759501B2 (en) 2023-09-19
US20220362346A1 (en) 2022-11-17
JP2015512374A (ja) 2015-04-27
PL3488857T3 (pl) 2023-12-11
RS64460B1 (sr) 2023-09-29
MY171146A (en) 2019-09-27
HUE062740T2 (hu) 2023-12-28
US20240016897A1 (en) 2024-01-18
CN104203266A (zh) 2014-12-10
ES2690553T3 (es) 2018-11-21
PL2827885T3 (pl) 2019-01-31
KR102072202B1 (ko) 2020-01-31
RU2014141700A (ru) 2016-05-20
SMT201800491T1 (it) 2018-11-09
US20220331404A1 (en) 2022-10-20
EP2827885B1 (en) 2018-08-15
EP3488857C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
HRP20231060T1 (hr) Pripravci peptida glp-1 i njihova priprava
JP2015512374A5 (enExample)
EP4331667A3 (en) Compositions comprising a delivery agent and preparation thereof
JP2015517488A5 (enExample)
EA201490149A1 (ru) Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения
EA201391758A1 (ru) Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
WO2015086686A3 (en) Protease resistant peptides
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
WO2015107536A3 (en) Fixed dose combination comprising linagliptin and metformin hci
EA201591097A1 (ru) Фармацевтическая композиция, содержащая кандесартана цилексетил и амлодипин
HRP20180316T1 (hr) Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala
MX2018005363A (es) Composicion farmaceutica destinada para administrarse a la mucosa nasal.
JP2017517561A5 (enExample)
EA201990129A1 (ru) Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
EA201592297A1 (ru) Композиции агомелатина, содержащие агомелатин в форме сокристаллов
EA201791458A1 (ru) Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта
MX374223B (es) Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
CY1120767T1 (el) Συνθεσεις glp-1 πεπτιδιων και παρασκευη αυτων
RU2013154071A (ru) Лекарственное средство и способ лечения головокружений
RU2012129783A (ru) Способ получения высокодисперсных форм лекарственных веществ и фармацевтических композиций
RU2011127058A (ru) Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2013154072A (ru) Лекарственное средство для лечения кинетозов и способ лечения кинетозов
CN105412148A (zh) 一种去除脚臭的喷剂及其制备方法